Every Monday I share a startup that I really like.
I call it the Red-Hot Innovator of the Week.
I spent years as as an R&D startup leader trying to get a synthetic medial meniscus through FDA. We didn’t get there — and that failure is the point.
For the 30- to 65-year-old with early OA and a worn-out meniscus, the options are still injection, scope, or wait for a knee replacement they aren’t ready for. That gap is real, and it has not closed. A meniscus replacement that actually works would change the trajectory of this industry.
Implant companies wait for the joint to fail.
This Dutch startup wants the shock absorber back first.
Company: ATRO Medical (Nijmegen, Netherlands)
Founded: 2016 (Radboudumc / DSM spin-off)
Core Product: Artimis (anatomic synthetic PCU meniscus)
The Problem: The Post-Meniscectomy "Dead Zone"
Roughly 20% of meniscectomy patients suffer persistent severe pain. These patients (typically ages 30–65) still have usable cartilage, creating a treatment gap:
No Middle Option: Past the point of simple repair; allografts face donor shortages; braces buy limited time; total knee arthroplasty (TKA) is too extreme for their cartilage state.
Loss of the Sho...
